Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.

Perera D, Venkitaraman AR.

Sci Rep. 2016 Jul 14;6:29741. doi: 10.1038/srep29741.

2.

Aurora-A Kinase as a Promising Therapeutic Target in Cancer.

D'Assoro AB, Haddad T, Galanis E.

Front Oncol. 2016 Jan 6;5:295. doi: 10.3389/fonc.2015.00295. eCollection 2015. Review.

3.

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma.

Restall IJ, Parolin DA, Daneshmand M, Hanson JE, Simard MA, Fitzpatrick ME, Kumar R, Lavictoire SJ, Lorimer IA.

Cell Cycle. 2015;14(18):2938-48. doi: 10.1080/15384101.2015.1071744.

4.

Genetics and epigenetics of sporadic thyroid cancer.

Vu-Phan D, Koenig RJ.

Mol Cell Endocrinol. 2014 Apr 5;386(1-2):55-66. doi: 10.1016/j.mce.2013.07.030. Epub 2013 Aug 8. Review.

5.

A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability.

Orr B, Compton DA.

Front Oncol. 2013 Jun 27;3:164. doi: 10.3389/fonc.2013.00164. Print 2013.

6.

Genomic instability and colon carcinogenesis: from the perspective of genes.

Rao CV, Yamada HY.

Front Oncol. 2013 May 21;3:130. doi: 10.3389/fonc.2013.00130. eCollection 2013.

7.

RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J.

Oncogene. 2014 May 1;33(18):2385-94. doi: 10.1038/onc.2013.182. Epub 2013 May 27.

8.

A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Omolo B, Carson C, Chu H, Zhou Y, Simpson DA, Hesse JE, Paules RS, Nyhan KC, Ibrahim JG, Kaufmann WK.

Cell Cycle. 2013 Apr 1;12(7):1071-82. doi: 10.4161/cc.24067. Epub 2013 Mar 1.

9.

Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase.

Shen L, Nishioka T, Guo J, Chen C.

Cancer Res. 2012 Dec 1;72(23):6153-62. doi: 10.1158/0008-5472.CAN-12-1862. Epub 2012 Oct 1.

10.

A MEK-independent role for CRAF in mitosis and tumor progression.

Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA.

Nat Med. 2011 Nov 13;17(12):1641-5. doi: 10.1038/nm.2464.

11.

Mechanisms of aneuploidy induction by RAS and RAF oncogenes.

Kamata T, Pritchard C.

Am J Cancer Res. 2011;1(7):955-71. Epub 2011 Mar 29.

12.

RAS oncogenes: weaving a tumorigenic web.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D.

Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Review.

13.

The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.

Ahmad EI, Gawish HH, Al Azizi NM, Elhefni AM.

Onco Targets Ther. 2011;4:115-21. doi: 10.2147/OTT.S12602. Epub 2011 Jul 15.

14.
15.

Molecular characterization of apoptosis induced by CARF silencing in human cancer cells.

Cheung CT, Singh R, Yoon AR, Hasan MK, Yaguchi T, Kaul SC, Yun CO, Wadhwa R.

Cell Death Differ. 2011 Apr;18(4):589-601. doi: 10.1038/cdd.2010.129. Epub 2010 Nov 5. Erratum in: Cell Death Differ. 2011 Jul;18(7):1238.

16.

Induction of the apoptosis inhibitor ARC by Ras in human cancers.

Wu L, Nam YJ, Kung G, Crow MT, Kitsis RN.

J Biol Chem. 2010 Jun 18;285(25):19235-45. doi: 10.1074/jbc.M110.114892. Epub 2010 Apr 14.

17.

Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7979-84. doi: 10.1073/pnas.0900343106. Epub 2009 Apr 29.

18.

Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Fagin JA, Mitsiades N.

Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):955-69. doi: 10.1016/j.beem.2008.09.017. Review.

19.

Bypass of hexavalent chromium-induced growth arrest by a protein tyrosine phosphatase inhibitor: enhanced survival and mutagenesis.

Bae D, Camilli TC, Chun G, Lal M, Wright K, O'Brien TJ, Patierno SR, Ceryak S.

Mutat Res. 2009 Jan 15;660(1-2):40-6. doi: 10.1016/j.mrfmmm.2008.10.006. Epub 2008 Oct 21.

20.

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD.

J Clin Oncol. 2008 Oct 1;26(28):4603-9. doi: 10.1200/JCO.2007.14.0418. Epub 2008 Jun 16.

Supplemental Content

Support Center